Navigation Links
Hooper Holmes Updates Guidance
Date:2/20/2008

ting new technology platforms and developing new product portfolios enabled Mony to generate significant growth.

Prior to joining Mony, Roy was Senior Vice President for Manulife, US, where his responsibilities included developing and implementing a multiple distribution channel strategy to reinvigorate insurance sales and eliminate distribution expense losses.

For the first 24 years of his career Roy was with Cigna, where he served as an agent, agency manager and senior executive. As Senior Vice President, he was responsible for half of Cigna's career agency sales force. He also ran the distribution and field service unit for Cigna's Pension Division and built the Annuity Division.

Roy received his B.S. degree from Eastern Michigan University and his M.B.A. from Loyola College. He holds CLU and ChFC professional certifications and has pursued advanced studies at Wharton and the Kellogg School of Business.

About Hooper Holmes

Hooper Holmes is the leader in collecting personal health data and transforming it into useful information, enabling customers to take actions that manage or reduce their risks and expenses. As the leading provider of risk assessment services for the insurance industry, Hooper Holmes provides insurers with the widest range of medical exam, data collection, laboratory testing and underwriting services in the industry.

With presence in over 250 markets and a network of more than 9,000 examiners, Hooper Holmes can arrange a medical exam anywhere in the U.S. and deliver the results to its customers. Each year we arrange more than 2.3 million medical exams and process 3.8 million specimens in our laboratory. We provide a complete service for wellness, disease management, and managed care companies including scheduling support, fulfillment of supplies, blood collection kits, medical screenings, lab testing and data transmission. We underwrite 300,000 cases annually and complete more than two million telephone
'/>"/>

SOURCE Hooper Holmes
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Hooper Holmes Marks 50,000 Health and Wellness Screenings
2. Hooper Holmes Announces Third Quarter 2007 Results
3. Hooper Holmes Appoints Leslie Hudson, PhD, to Board of Directors
4. Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information
5. Hooper Holmes Introduces Mature Assessment
6. Hooper Holmes to Exhibit at the 2007 Sixth Annual Association of Home Office Underwriters Conference
7. Hooper Holmes Concludes Sale of Medicals Direct
8. Hooper Holmes Launches Health & Wellness Division at 2007 Disease Management Leadership Forum and Integrated Care Summit
9. Hooper Holmes Names Chris Behling President of Health & Wellness Division
10. Veridigm (VRGD) Updates Shareholders
11. NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...linical trial results could lead to availability o...eatment for deep lines and wrinkles by 2009. , ... 24, 2008 -- Gel-Del Technologies , a St. Paul, M... that it has concluded clinical trials of CosmetaL...als say holds potential to be a more effective alt...
(Date:7/24/2008)...ll/ --, Key Highlights, Misys plc (LSE: MSY) del...sing targets for the next phase of the turnaround....%, bringing Group operating profit(2) to GBP81m,3...trategy and entering,into the next phase of the tu...o view the Multimedia News Release, please click:,...
(Date:7/23/2008)...wire/ -- MediVoice(R), LLC, the,world,s first mobi...escribing, has formed a strategic partnership with... web-based, patient-centered health record,managem...e and market its,mobile voice-activation solution ...., "MediVoice is pleased to develop a strategic p...
(Date:7/23/2008)..., July 23 /PRNewswire-FirstCall/ - Cardiome Pharma...t it has entered into an,agreement with CR Intrins...,CR Intrinsic Investors, LLC, an affiliate of S.A....ertible preferred shares for gross proceeds of,US$... for general corporate,purposes, costs associated ...
Breaking Medicine News(10 mins):Health News:Clinical Trial Concluded For New Wrinkle Treatment 2Health News:Clinical Trial Concluded For New Wrinkle Treatment 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 2Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 4Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 2Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 3Health News:Cardiome Announces Preferred Share Financing 2Health News:Cardiome Announces Preferred Share Financing 3
.... Ragnfrid H. Nordbo, of the Norwegian Institute o...d set of people// suffering anorexia nervosa, a fo...his mental disease attribute a great deal of impor...a deep seated need or emotion. In his estimate, t...
...n, 81, the famous Pulitzer Prize-winning novelist,...usetts.// According to his daughter, Alexandra, he... He belonged to Virginia. He was obsessive about r...im write novels like "Lie Down In Darkness" and "T...
...a government data, the number of deaths due to alc...The Office for National Statistics (ONS) revealed ... in the year 1991 and it has risen to 8,386 by las...s, the lower price and easy accessibility are resp...
...hich has been one of the major causes of death in ...and in the next two decades// according to the Chi...Dr Harry Burns, "In the 1960s, one in 100 men died...ing all the time and, thanks to the smoking ban, I...
Other Medicine News:Health News:Deaths due to heavy drinking has doubled in 15 years 2Health News:Eradication of Lung Cancer in 20 years 2Health News:Eradication of Lung Cancer in 20 years 3
(Date:7/22/2008)...y Demonstrates Feasibility and Efficacy of Treatin...iver Cancer, SAN FRANCISCO, and YONGIN-SI, South ... Francisco, CA and Ottawa, Ontario), and its South... that novel findings from,a Phase I clinical trial...rated that the product was well-tolerated and resu...
(Date:7/22/2008)...TH SAN FRANCISCO, Calif., July 22 /- ...t has completed patient enrollment,in its Phase 1/...ity and,ammonia scavenging effects of HPN-100 (for...ylbutyrate) in patients with urea cycle disorders,...lts in the fourth quarter,of this year., (Logo: ...
(Date:7/22/2008)...HIA ANTIPOLIS, France, July 22 /PRNewswire-FirstCa...unced it has successfully completed the,enrollment...ed hypertension,in two clinical pharmacology studi...nnounced timelines. These trials are designed to a...n comparison to ibuprofen and,naproxen, using the ...
(Date:7/21/2008)... YORK, July 21 /- Ari Kiev, M.D., pre... speaker at the upcoming conference Wall,Street Un...ement,s Guide to,Wall Street. The conference will ...errace, 267 Fifth Avenue in New York. The event is...d mid-cap life science companies to gain,better in...
Breaking Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Coherent Inc to Webcast First Fiscal Quarter 2008 Results 9937 1Dave Perbix Named Vice President Occupational Health Sales and Marketing for Kaiser Permanente 9933 1Dave Perbix Named Vice President Occupational Health Sales and Marketing for Kaiser Permanente 9933 2Vapotherm 28R 29 Announces Validation of U S Patent 2694 1Vapotherm 28R 29 Announces Validation of U S Patent 2694 2Clinimetrics Celebrates 20th Anniversary in Contract Research Business 2690 1
...FirstCall/ -- Vical,Incorporated today announced t...d positive results following interim analysis of d... 3 trial of an,angiogenesis product candidate usin...ndings that the primary efficacy,endpoint in the t...ce and that there were no major safety concerns re...
...AMADEO, one of the,first studies to compare the p...ockers in hypertensive patients with,diabetic nep...f Hypertension, Milan. The results from this study...ignificantly greater extent,than losartan.(1) ...ss, Foothills Hospital,in Calgary, Canada said "T...
Other Medicine Technology:Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 2Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 3Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 4Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 5New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 2New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 3New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 5
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum.
...igned as a high throughput primary or backup instr...r offers performance and reliability equal to or g...advanced technology of the AUTION JET AJ-4270 and ...ate results, limiting interference from elevated p...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity
...rone Sulfate (E1S) is the most abundant circulatin... men [1,2]. Estrone Sulfate is a major metabolite ...fe in blood [2,3]. In premenopausal women, estrone...e and estradiol, rising gradually during the folli...
Medicine Products: